This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
The OralCDx Brush Biopsy (e.g., BrushTest®) is considered experimental/investigational and therefore, non-covered. There is insufficient evidence in medical literature to support the effectiveness of this procedure. The data are insufficient to permit scientific conclusions regarding the role of OralCDx Brush Biopsy in the diagnosis of cancer.
Experimental/Investigational (E/I) services are not covered regardless of place of service.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.